skip to main content
Idioma:
Refinado por: assunto: Male remover assunto: Treatment Outcome remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
Material Type:
Artigo 		Adicionar ao Meu Espaço

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

Romer, A. ; Seiler, D. ; Marincek, N. ; Brunner, P. ; Koller, M. T. ; Ng, Q. K. T. ; Maecke, H. R. ; Müller-Brand, J. ; Rochlitz, C. ; Briel, M. ; Schindler, C. ; Walter, M. A.

European journal of nuclear medicine and molecular imaging, 2014-02, Vol.41 (2), p.214-222 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
2
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Marincek, Nicolas ; Jörg, Ann-Catherine ; Brunner, Philippe ; Schindler, Christian ; Koller, Michael T ; Rochlitz, Christoph ; Müller-Brand, Jan ; Maecke, Helmut R ; Briel, Matthias ; Walter, Martin A

Journal of translational medicine, 2013-01, Vol.11 (1), p.17-17, Article 17 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
3
An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer
An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

Salzberg, Marc ; Rochlitz, Christoph ; Morant, Rudolf ; Thalmann, George ; Pedrazzini, Augusto ; Roggero, Enrico ; Schönenberger, Astrid ; Knuth, Alexander ; Borner, Markus

Oncology research and treatment, 2007-07, Vol.30 (7), p.355-360 [Periódico revisado por pares]

Freiburg, Germany

Texto completo disponível

Citações Citado por
4
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels
Material Type:
Artigo 		Adicionar ao Meu Espaço

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels

Rochlitz, Christoph ; Dreno, Brigitte ; Jantscheff, Peter ; Cavalli, Franco ; Squiban, Patrick ; Acres, Bruce ; Baudin, Martine ; Escudier, Bernard ; Heinzerling, Lucie ; Morant, Rudolf ; Herrmann, Richard ; Dietrich, Pierre-Yves ; Dummer, Reinhard

Cancer gene therapy, 2002-03, Vol.9 (3), p.289-295 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
5
P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients
P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients

Boulay, J L ; Perruchoud, A P ; Reuter, J ; Bolliger, C ; Herrmann, R ; Rochlitz, C

Cancer gene therapy, 2000-09, Vol.7 (9), p.1215-1219 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
6
Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors : mechanism(s) of elimination of the transgene-carrying cells
Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors : mechanism(s) of elimination of the transgene-carrying cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors : mechanism(s) of elimination of the transgene-carrying cells

JANTSCHEFF, P ; HERRMANN, R ; SPAGNOLI, G ; REUTER, J ; MEHTALI, M ; COURTNEY, M ; ROCHLITZ, C

Cancer Immunology, Immunotherapy, 1999-09, Vol.48 (6), p.321-330 [Periódico revisado por pares]

Berlin: Springer

Texto completo disponível

Citações Citado por
7
Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)
Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)

ROCHLITZ, C ; LOHRI, A ; BACCHI, M ; SCHMIDT, M ; NAGEL, S ; FOPP, M ; FEY, M. F ; HERRMANN, R ; NEUBAUER, A

Leukemia, 1999-09, Vol.13 (9), p.1352-1358 [Periódico revisado por pares]

London: Nature Publishing

Texto completo disponível

Citações Citado por
8
A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer

Schuler, M ; Rochlitz, C ; Horowitz, J A ; Schlegel, J ; Perruchoud, A P ; Kommoss, F ; Bolliger, C T ; Kauczor, H U ; Dalquen, P ; Fritz, M A ; Swanson, S ; Herrmann, R ; Huber, C

Human gene therapy, 1998-09, Vol.9 (14), p.2075-2082 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de1998  (1)
  2. 1998Até1998  (1)
  3. 1999Até1999  (2)
  4. 2000Até2002  (2)
  5. Após 2002  (3)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.